Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: A multicenter study

被引:74
作者
Sundar, S
Jha, TK
Thakur, CP
Mishra, M
Singh, VP
Buffels, R
机构
[1] Banaras Hindu Univ, Kalaazar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India
[2] Kalaazar Res Ctr, Muzaffarpur 842001, India
[3] Balaji Uthan Sansthan, Patna 800001, Bihar, India
[4] Kalaazar Res Ctr, Darbhanga 846001, India
[5] Gilead Sci Inc, F-75017 Paris, France
关键词
D O I
10.4269/ajtmh.2002.66.143
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In this randomized, double-blind, dose-ranging, multicenter trial, 84 patients with visceral leishmaniasis refractory to antimony therapy were administered liposomal amphotericin B (AmBisome) at cumulative doses of 3.75, 7.5, and 15.0 mg/kg for 5 consecutive days. Posttreatment apparent cure and definite cure were assessed at 2 weeks and 6 months after the end of therapy, respectively. Mild to moderate infusion-related fever and rigors were seen in 29 and 44% of patients, respectively. One patient each in the 3.75- and 7.5-mg groups had detectable parasites on splenic smear at posttreatment evaluation. At 6 months' follow-up, however, 2, 1, and 1 patients relapsed in the 3.75-. 7.5-, and 15.0-mg groups, resulting in definite cure rates of 89, 93, and 97%, respectively. There was no significant difference in the cure rates of the 3 groups. Low-dose liposomal amphotericin B given for 5 days can cure most patients with Indian kala-azar.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 17 条
[1]  
Berman JD, 1998, B WORLD HEALTH ORGAN, V76, P25
[2]  
Bora D, 1999, NATL MED J INDIA, V12, P62
[3]  
DAVIDSON RN, 1994, Q J MED, V87, P75
[4]   TREATMENT OF BRAZILIAN KALA-AZAR WITH A SHORT-COURSE OF AMPHOCIL (AMPHOTERICIN-B CHOLESTEROL DISPERSION) [J].
DIETZE, R ;
MILAN, EP ;
BERMAN, JD ;
GROGL, M ;
FALQUETO, A ;
FEITOSA, TF ;
LUZ, KG ;
SUASSUNA, FAB ;
MARINHO, LAC ;
KSIONSKI, G .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (06) :981-986
[5]  
Jha S N, 1991, J Assoc Physicians India, V39, P314
[6]   USE OF AMPHOTERICIN-B IN DRUG-RESISTANT CASES OF VISCERAL LEISHMANIASIS IN NORTH BIHAR, INDIA [J].
JHA, TK ;
GIRI, YN ;
SINGH, TK ;
JHA, S .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1995, 52 (06) :536-538
[7]   US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis [J].
Meyerhoff, A .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :42-48
[8]   AMPHOTERICIN VERSUS PENTAMIDINE IN ANTIMONY-UNRESPONSIVE KALA-AZAR [J].
MISHRA, M ;
BISWAS, UK ;
JHA, DN ;
KHAN, AB .
LANCET, 1992, 340 (8830) :1256-1257
[9]   LIPOSOMAL AMPHOTERICIN-B (AMBISOME) IN THE TREATMENT OF COMPLICATED KALA-AZAR UNDER FIELD CONDITIONS [J].
SEAMAN, J ;
BOER, C ;
WILKINSON, R ;
DEJONG, J ;
DEWILDE, E ;
SONDORP, E ;
DAVIDSON, R .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (01) :188-193
[10]   Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex [J].
Sundar, S ;
Murray, HW .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03) :762-765